Form 4: Myriad Genetics Inc. Executive Awarded Restricted Stock Units

Myriad Genetics Inc. executive Mark Steven Davis was granted 22,816 restricted stock units under the company's 2017 equity incentive plan.

Summary

• Myriad Genetics Inc. granted 22,816 restricted stock units to executive Mark Steven Davis on December 10, 2024.
• These restricted stock units were awarded under the company's 2017 Employee, Director and Consultant Equity Incentive Plan.
• Each restricted stock unit represents a contingent right to receive one share of the company's common stock.
• The units vest on the anniversary of the grant date.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively for aligning interests, but has a minor dilutionary effect.

Positives

• The grant of restricted stock units aligns executive interests with the company's performance.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the restricted stock units is subject to the volatility of the company's stock price.
• The vesting of the units could lead to dilution of existing shareholders' equity.

Industry Context

Stock-based compensation is a common practice in the biotechnology industry to attract and retain key talent and align their interests with shareholders.

Comparison to Industry Standards

• Many biotechnology companies use restricted stock units as part of their executive compensation packages.
• The vesting schedule of one year is fairly standard for these types of grants.
• Companies like Illumina and Exact Sciences also use similar equity-based compensation plans.

Stakeholder Impact

• Shareholders may experience minor dilution due to the issuance of new shares upon vesting.
• The executive is incentivized to improve company performance, which benefits all stakeholders.

Key Dates

Keywords

restricted stock units, equity incentive plan, stock grant, executive compensation, Myriad Genetics, MYGN